Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

National Survey on Dyslipidemic Patients (PRYSME)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 18, 2008
Last updated: August 4, 2009
Last verified: August 2009

The purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Survey on Time to Lipid-lowering Drug Implementation on Dyslipidemic Patients in General Practice.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • time to lipid-lowering drug implementation (immediately, treatment within a period 0-3 month and > 3 month, according to the cardiovascular risk level, (0 risk factor, 1 risk factor, 2 risk factors, ≥ 3 risk factors, secondary prevention). [ Time Frame: Once ] [ Designated as safety issue: No ]

Enrollment: 3655
Study Start Date: June 2008
Study Completion Date: January 2009

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First three consecutive dyslipidemic patients seen by GP


Inclusion Criteria:

  • Diagnosis of dyslipemia made less than 2 years
  • Treated by a lipid-lowering drug
  • Agree to take part in the survey

Exclusion Criteria:

  • Patient included in a clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00701402

  Show 1207 Study Locations
Sponsors and Collaborators
Study Director: Alain Castaigne AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals Identifier: NCT00701402     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2007/9
Study First Received: June 18, 2008
Last Updated: August 4, 2009
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
time to lipid-lowering drug implementation
dyslipidemic patients

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 25, 2014